Differentiation therapy targeting the stalled epigenetic developmental programs in pediatric high-grade gliomas

IF 10.5 2区 医学 Q1 PHARMACOLOGY & PHARMACY Pharmacological research Pub Date : 2025-02-01 Epub Date: 2025-01-14 DOI:10.1016/j.phrs.2025.107599
Wang Xiang , Xiaolin Zhang , Minhai Dong , Lijun Wan , Bin Zhang , Feng Wan
{"title":"Differentiation therapy targeting the stalled epigenetic developmental programs in pediatric high-grade gliomas","authors":"Wang Xiang ,&nbsp;Xiaolin Zhang ,&nbsp;Minhai Dong ,&nbsp;Lijun Wan ,&nbsp;Bin Zhang ,&nbsp;Feng Wan","doi":"10.1016/j.phrs.2025.107599","DOIUrl":null,"url":null,"abstract":"<div><div>Pediatric high-grade gliomas (pHGGs) are the most common brain malignancies in children and are characterized by blocked differentiation. The epigenetic landscape of pHGGs, particularly the H3K27-altered and H3G34-mutant subtypes, suggests these tumors may be particularly susceptible to strategies that target blocked differentiation. Differentiation therapy aims to overcome this differentiation blockade by promoting glioma cell differentiation into more mature and less malignant cells. Epigenetic modulators, including inhibitors of histone deacetylase (HDAC), enhancer of zeste homolog 2 (EZH2), BRG1/BRM-associated factor (BAF) complex, have shown promise in preclinical studies of pHGGs by altering the differentiation program of glioma cells. Although challenges remain in overcoming tumor cell heterogeneity, induced differentiation therapy holds promise for treating these currently incurable pediatric brain cancers.</div></div>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":"212 ","pages":"Article 107599"},"PeriodicalIF":10.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043661825000246","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Pediatric high-grade gliomas (pHGGs) are the most common brain malignancies in children and are characterized by blocked differentiation. The epigenetic landscape of pHGGs, particularly the H3K27-altered and H3G34-mutant subtypes, suggests these tumors may be particularly susceptible to strategies that target blocked differentiation. Differentiation therapy aims to overcome this differentiation blockade by promoting glioma cell differentiation into more mature and less malignant cells. Epigenetic modulators, including inhibitors of histone deacetylase (HDAC), enhancer of zeste homolog 2 (EZH2), BRG1/BRM-associated factor (BAF) complex, have shown promise in preclinical studies of pHGGs by altering the differentiation program of glioma cells. Although challenges remain in overcoming tumor cell heterogeneity, induced differentiation therapy holds promise for treating these currently incurable pediatric brain cancers.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对小儿高级别胶质瘤停滞的表观遗传发育程序的分化治疗。
小儿高级别胶质瘤(pHGGs)是儿童中最常见的脑恶性肿瘤,其特征是分化受阻。pHGGs的表观遗传格局,特别是h3k27改变和h3g34突变亚型,表明这些肿瘤可能特别容易受到靶向阻断分化策略的影响。分化治疗旨在通过促进胶质瘤细胞分化为更成熟和恶性程度更低的细胞来克服这种分化阻断。表观遗传调节剂,包括组蛋白去乙酰化酶(HDAC)抑制剂、zeste同源物2增强剂(EZH2)、BRG1/ brm相关因子(BAF)复合物,通过改变胶质瘤细胞的分化程序,在pHGGs的临床前研究中显示出前景。尽管在克服肿瘤细胞异质性方面仍存在挑战,诱导分化疗法有望治疗目前无法治愈的儿童脑癌。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacological research
Pharmacological research 医学-药学
CiteScore
18.70
自引率
3.20%
发文量
491
审稿时长
8 days
期刊介绍: Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.
期刊最新文献
Mapping the evolution of the forced swim test across interpretation, welfare and pharmacology TSPO-mediated mitochondrial retrograde signaling primes the microglial NLRP3 inflammasome The crossroads of inflammation and oxidative stress: A review of the interplay between eicosanoids and reactive oxygen species tRNA-derived small RNAs in pulmonary diseases: Regulatory functions and clinical prospects Proteolysis-targeting Chimeras induce ferroptosis in cancer: From Mechanism to clinical application
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1